Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PYPD 
PolyPid (PYPD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PYPD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.41% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.02M USD | Price to earnings Ratio - | 1Y Target Price 11.33 |
Price to earnings Ratio - | 1Y Target Price 11.33 | ||
Volume (30-day avg) 13859 | Beta 1.27 | 52 Weeks Range 2.37 - 5.09 | Updated Date 04/1/2025 |
52 Weeks Range 2.37 - 5.09 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -86.31% | Return on Equity (TTM) -1038.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21992833 | Price to Sales(TTM) - |
Enterprise Value 21992833 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.36 | Shares Outstanding 10190900 | Shares Floating 4590187 |
Shares Outstanding 10190900 | Shares Floating 4590187 | ||
Percent Insiders 25.09 | Percent Institutions 53.36 |
Analyst Ratings
Rating 4 | Target Price 11 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PolyPid
Company Overview
History and Background
PolyPid, founded in 2008, is a biopharmaceutical company focused on developing and commercializing products utilizing its PLEX technology to deliver drugs locally and over a prolonged period. It aims to improve surgical outcomes by reducing infection rates and promoting healing.
Core Business Areas
- Surgical Site Infection (SSI) Prevention: Developing and commercializing products designed to prevent SSIs following surgical procedures.
- Local Drug Delivery: Utilizing the PLEX technology platform to create products for targeted drug delivery at the site of medical need.
Leadership and Structure
PolyPid is led by a management team with experience in pharmaceuticals, biotechnology, and medical devices. The company has a board of directors providing oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- D-PLEX100: D-PLEX100 is PolyPid's lead product candidate, designed to prevent SSIs after surgery. Clinical trials have shown its efficacy in reducing SSIs. Competitors include traditional antibiotic treatments and other preventative measures.
Market Dynamics
Industry Overview
The surgical site infection prevention market is growing, driven by increasing surgical volumes and the need to reduce healthcare costs associated with infections.
Positioning
PolyPid aims to position itself as a leader in SSI prevention with D-PLEX100, offering a novel approach to local antibiotic delivery.
Total Addressable Market (TAM)
The global SSI market is estimated to be in the billions of dollars. PolyPid aims to capture a significant portion of this TAM with its innovative D-PLEX100 product.
Upturn SWOT Analysis
Strengths
- Novel PLEX technology platform
- Positive clinical trial results for D-PLEX100
- Focus on addressing a significant unmet medical need
Weaknesses
- Limited commercialization experience
- Reliance on a single lead product
- Need for further clinical data to support market adoption
Opportunities
- Expanding D-PLEX100 applications to other surgical procedures
- Developing new products based on the PLEX technology
- Partnering with larger pharmaceutical companies for commercialization
Threats
- Competition from established antibiotic treatments
- Regulatory hurdles and approval timelines
- Potential for adverse events in clinical trials or post-market
Competitors and Market Share
Key Competitors
- MTOR
- BCT
- STBA
Competitive Landscape
PolyPid's competitive advantage lies in its novel PLEX technology for local drug delivery. However, it faces competition from established pharmaceutical companies with broader product portfolios.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: PolyPid's historical growth is tied to its R&D progress and clinical trial results.
Future Projections: Future growth depends on regulatory approval and successful commercialization of D-PLEX100. Analyst estimates vary widely at this stage.
Recent Initiatives: Recent initiatives include completing clinical trials for D-PLEX100 and preparing for regulatory submissions.
Summary
PolyPid is a biopharmaceutical company developing innovative solutions for surgical site infections. Their PLEX technology and lead product, D-PLEX100, have shown promise in clinical trials. However, the company faces risks related to regulatory approval, commercialization, and competition from established players. Continued successful trial data is vital for future success.
Similar Companies
STBA
S&T Bancorp Inc
STBA
S&T Bancorp Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Clinical trial data
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Financial data is based on currently available information and may be subject to change. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PolyPid
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-06-26 | CEO & Director Ms. Dikla Czaczkes Akselbrad | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://www.polypid.com |
Full time employees 57 | Website https://www.polypid.com | ||
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.